nivolumab,ipilimumab
bms
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'niche-2', 'vanda']
there is a difference between "practice-changing" and "revolutionary". niche-2 results on neo-ajuvant io in msi-h stage iii crc are firmly in the second category. i look forward to 3-year dfs q4 2023!!! #esmo2022 
MD with PhD in neuro-endocrine tumors. Digestive oncologist @UZAnieuws, coordinator @enetwerkbe, secretary @dbnetsociety, editor @EndoCancer.